ACHV
Achieve Life Sciences, Inc. NASDAQ Listed Oct 12, 1995$4.79
Mkt Cap $254.9M
52w Low $2.00
69.2% of range
52w High $6.03
50d MA $3.96
200d MA $3.95
P/E (TTM)
-3.5x
EV/EBITDA
-3.9x
P/B
8.9x
Debt/Equity
0.7x
ROE
-254.0%
P/FCF
-4.4x
RSI (14)
—
ATR (14)
—
Beta
1.96
50d MA
$3.96
200d MA
$3.95
Avg Volume
972.5K
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
1040 West Georgia Street · Vancouver, BC V6E 4H1 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.27 | -0.28 | -3.7% | 2.90 | +4.5% | -2.8% | -0.3% | -8.6% | -7.9% | +1.4% | — |
| Nov 6, 2025 | AMC | -0.24 | -0.28 | -16.7% | 4.74 | -1.5% | -3.2% | -6.1% | +0.6% | -0.4% | -3.4% | — |
| Aug 7, 2025 | AMC | -0.37 | -0.37 | +0.0% | 2.64 | -1.9% | -5.3% | -7.2% | -7.6% | -3.8% | -3.4% | — |
| May 13, 2025 | AMC | -0.37 | -0.37 | +0.0% | 2.65 | -0.4% | -6.4% | +3.0% | +16.2% | +24.9% | +23.0% | — |
| Mar 11, 2025 | AMC | -0.30 | -0.36 | -20.0% | 2.92 | +0.3% | -9.2% | -9.2% | -5.5% | -0.3% | -4.8% | — |
| Nov 7, 2024 | AMC | -0.26 | -0.36 | -38.5% | 5.00 | -5.4% | -7.4% | -10.6% | -7.0% | -9.4% | -12.2% | — |
| Aug 13, 2024 | AMC | -0.22 | -0.25 | -13.6% | 4.36 | -1.4% | +0.5% | +2.1% | +3.2% | +6.2% | +1.1% | — |
| May 9, 2024 | AMC | -0.24 | -0.26 | -8.3% | 4.53 | +2.6% | +1.8% | +6.2% | +10.6% | +15.0% | +11.9% | — |
| Mar 28, 2024 | AMC | -0.32 | -0.26 | +18.8% | 4.55 | +2.0% | +0.7% | -1.5% | +0.9% | -1.5% | -2.0% | — |
| Nov 9, 2023 | AMC | -0.34 | -0.34 | +0.0% | 4.19 | +0.6% | -1.9% | +0.2% | +7.4% | +16.0% | +22.7% | — |
| Aug 14, 2023 | AMC | -0.41 | -0.43 | -4.9% | 5.35 | -1.7% | -3.0% | -7.3% | -6.5% | -8.4% | -8.8% | — |
| May 9, 2023 | AMC | -0.65 | -0.50 | +23.1% | 8.81 | +1.8% | +12.7% | +0.8% | -6.7% | -11.0% | -10.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | Canaccord Genuity | Initiates | Buy | $13 | $4.25 | $4.37 | +2.8% | -0.9% | -0.5% | -2.4% | -5.4% | -6.8% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.55 | $4.05 | +14.1% | +35.5% | +43.7% | +19.7% | +18.6% | +19.2% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $3.03 | +4.5% | -2.8% | -0.3% | -8.6% | -7.9% | +1.4% |
| Aug 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.38 | $4.49 | +2.5% | +1.6% | +2.7% | +5.7% | +0.7% | +1.4% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.61 | $4.68 | +1.5% | +4.3% | +8.7% | +13.0% | +10.0% | +8.5% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.55 | $4.64 | +2.0% | +0.7% | -1.5% | +0.9% | -1.5% | -2.0% |
| Mar 5 | Lake Street | Maintains | Buy → Buy | — | $4.42 | $4.40 | -0.5% | -0.7% | +0.2% | -0.9% | -0.7% | -1.6% |
| Dec 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.45 | $3.89 | -28.6% | -42.2% | -39.1% | -39.8% | -41.7% | -39.3% |
| May 31 | Lake Street | Maintains | Buy → Buy | — | $6.24 | $6.21 | -0.5% | -0.6% | +3.5% | +8.0% | +3.4% | +0.6% |
| May 10 | Lake Street | Maintains | Buy → Buy | — | $8.81 | $8.97 | +1.8% | +12.7% | +0.8% | -6.7% | -11.0% | -10.3% |
| Mar 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.44 | $4.54 | +2.3% | -2.0% | -1.4% | -1.4% | +5.9% | +6.1% |
| Nov 16 | Maxim Group | Maintains | Buy → Buy | — | $2.32 | $2.40 | +3.4% | -6.9% | -2.2% | +3.0% | +7.8% | +24.1% |
| Oct 4 | Alliance Global Partners | Maintains | Buy → Buy | — | $8.45 | $8.65 | +2.4% | +6.4% | +3.6% | -3.7% | -1.8% | -0.7% |
| Jun 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.93 | $8.50 | +7.2% | +5.8% | +4.5% | +5.3% | +17.9% | +14.4% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $8.93 | $8.80 | -1.5% | +1.6% | +1.9% | -3.5% | -3.8% | -15.0% |
| Nov 25 | Lake Street | Maintains | Buy → Buy | — | $8.93 | $8.80 | -1.5% | +1.6% | +1.9% | -3.5% | -3.8% | -15.0% |
| Nov 25 | Maxim Group | Maintains | Buy → Buy | — | $8.93 | $8.80 | -1.5% | +1.6% | +1.9% | -3.5% | -3.8% | -15.0% |
| Sep 17 | Lake Street | Maintains | Buy → Buy | — | $9.98 | $10.39 | +4.1% | +9.9% | +2.5% | -7.0% | -5.5% | -10.5% |
| Feb 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $10.00 | $11.20 | +12.0% | +4.0% | -2.0% | -6.0% | -4.0% | +6.0% |
| Jun 14 | Maxim Group | Maintains | Buy → Buy | — | $53.40 | $54.40 | +1.9% | -6.4% | -5.2% | -3.0% | -9.4% | -9.7% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CEO Richard Stewart's departure amid a private placement signals potential leadership instability and dilution concerns, warranting investor scrutiny on succession clarity and capital allocation rationale.
Apr 16
8-K
Unknown — 8-K Filing
Achieve's CEO signals confidence in cytisinicline's commercial potential as a first-in-class smoking cessation drug, positioning it as a transformative treatment that could significantly expand the addressable market if approved.
Mar 24
Data updated apr 24, 2026 10:32am
· Source: massive.com